Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies
Andrés Chang, Jean L. Koff, Lilin Lai, Victor M. Orellana‐Noia, Minal Surati, Alyssa Leal, Madison Ellis, Bushra Wali, Alberto Moreno, Susanne L. Linderman, Colin B. O’Leary, Pamela B. Allen, Michael C. Churnetski, Madhav V. Dhodapkar, Mehul S. Suthar, Jonathon B. Cohen, Rafi Ahmed
Abstract
To investigate the neutralizing activity of full dose AZD7442 against live, contemporary Omicron variants after administration to patients who are immunocompromised.
Topics & Concepts
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Virology2019-20 coronavirus outbreakSars virusMedicineBiologyInternal medicineDiseaseOutbreakInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing